Logo del repository
  1. Home
 
Opzioni

Sex Differences in Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants for Atrial Fibrillation: An ASPERA-R Inverse Probability Weighted Analysis

Foschi, Matteo
•
D'Anna, Lucio
•
Gabriele, Francesca
altro
Sacco, Simona
2026
  • journal article

Periodico
JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE
Abstract
Background: Sex-specific outcomes after breakthrough ischemic stroke on oral anticoagulation (OAC) are unexplored. We compared 90-day outcomes by sex and explored modifiers. Methods: ASPERA-R (Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants retrospective cohort; NCT06823466) was an international, multicenter, retrospective study enrolling adults (aged >18 years) with breakthrough ischemic stroke on OAC for atrial fibrillation. Primary outcome was 90-day return to baseline neurologic function (modified Rankin Scale [mRS] score 0-1 maintained if prestroke 0-1; or same/lower mRS score if prestroke ≥2). Secondary outcomes were 90-day mRS shift, recurrent ischemic stroke/transient ischemic attack, myocardial infarction, and all-cause and vascular death. Safety outcomes included 90-day moderate-to-severe bleeding, intracranial hemorrhage, 24-hour hemorrhagic transformation, and 24-hour symptomatic intracranial hemorrhage. We applied inverse probability weighting and regression models to compare outcomes. Prespecified subgroup analysis tested sex-specific interactions. Results: We included 1649 patients (women, 52.2%; mean±SD age, 78.0±10.7 years). Women were older (80.2±9.6 versus 76.3±10.8 years; unweighted standardized mean difference=0.376), had higher baseline National Institutes of Health Stroke Scale score (13 [interquartile range, 9-19] versus 9 [interquartile range, 4-17]; unweighted standardized mean difference=0.227), and worse prestroke mRS score (unweighted standardized mean difference=0.237). After weighting, women were less likely to return to baseline neurologic function (35.2% versus 42.7%; adjusted risk ratio, 0.82 [95% CI, 0.71-0.96]; P=0.015), had worse mRS distribution (adjusted odds ratio, 1.17 [95% CI, 1.01-1.37]; P=0.043), and had higher recurrent ischemic stroke/transient ischemic attack (4.8% versus 2.8%; adjusted hazard ratio [HR], 1.70 [95% CI, 1.01-2.86]; P=0.045). Women showed a trend toward more moderate-to-severe bleeding (4.6% versus 2.8%; adjusted HR, 1.63 [95% CI, 0.96-2.72]; P=0.070). Subgroup analyses revealed significant sex interactions for OAC type, competing cause, endovascular treatment, and OAC restart. Conclusions: Women had worse 90-day outcomes than men after breakthrough ischemic stroke on OAC for atrial fibrillation, highlighting the need for sex-aware management.
DOI
10.1161/JAHA.125.047064
Archivio
https://hdl.handle.net/11368/3129658
https://www.ahajournals.org/doi/10.1161/JAHA.125.047064
https://ricerca.unityfvg.it/handle/11368/3129658
Diritti
open access
license:creative commons
license:digital rights management non definito
license:digital rights management non definito
license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/
license uri:iris.pri00
license uri:iris.pri00
FVG url
https://arts.units.it/bitstream/11368/3129658/1/foschi-et-al-2026-sex-differences-in-outcomes-after-breakthrough-ischemic-stroke-on-oral-anticoagulants-for-atrial.pdf
Soggetti
  • direct oral anticoagu...

  • ischemic stroke

  • oral anticoagulant

  • outcome

  • sex difference

  • vitamin K antagonist

google-scholar
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your nstitution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Realizzato con Software DSpace-CRIS - Estensione mantenuta e ottimizzata da 4Science

  • Impostazioni dei cookie
  • Informativa sulla privacy
  • Accordo con l'utente finale
  • Invia il tuo Feedback